- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04804683
European/International FMD Registry and Initiative (FEIRI)
The European/International FMD Registry and Initiative (FEIRI), a Prospective Study
The main objectives of FEIRI are:
(i) To describe the demographic and arterial characteristics of FMD and related diseases at a global scale and according to countries and/or ethnic origin
(ii) To evaluate the incidence and predictors of novel FMD lesions and complications
(iii) To explore the commonalities and differences between FMD, SCAD and so-called atypical FMD (patients with multiple dissections and/or aneurysms without string-of-beads, focal stenosis or evidence of inherited arteriopathy)
(iv) To contribute to the unravelling of genetic, proteomic and molecular mechanisms underlying FMD and related diseases
Participation to the FEIRI study implies:
(i) Collection of demographic and standard-of-care clinical data, both retrospectively (from the diagnosis of FMD to signature of the informed consent) and prospectively (on the occasion of standard-of-care follow-up).
(ii) Optional participation to a biobank implying collection of blood, urine and, in rare cases of intervention, tissue samples for genomic and proteomic analysis and identification of diagnostic and prognostic biomarkers of FMD.
Participants will be enrolled in centres from over 20 countries in Europe and beyond.
Study Overview
Status
Conditions
Detailed Description
Fibromuscular dysplasia (FMD) is an idiopathic, segmental, nonatherosclerotic, and noninflammatory disease of the musculature of arterial walls, leading to stenosis of small- and medium-sized arteries. FMD can be classified in multifocal FMD, characterized by alternation of stenosis and dilations ("string-of-beads") and focal FMD, corresponding to a solitary narrowing. While for long FMD was considered as a rare cause of renovascular disease mostly affecting young women, during the last decades, joint international efforts have led to a thorough reappraisal of the disease. In summary, (i) FMD is no more considered as a truly rare disease; (ii) FMD may be also diagnosed in men (10-20%) and at all ages; (iii) beyond arterial stenosis, FMD is often associated with dissections, aneurysms and arterial tortuosity; (iv) FMD is not restricted to renal arteries and often affects two or more arterial beds; (iv) multifocal FMD lesions are frequent in patients with Spontaneous Coronary Artery Dissection (SCAD).
Despite traditional views on the role of female hormones, mechanical factors and smoking, the pathophysiology of FMD remains largely unknown. In the last decade, research has been focused on genetic dissection of the disease and identification of biomarkers. Recent advances include: (i) identification of an association between FMD and an intronic variant of the Phosphatase and actin regulator 1 (PHACTR1) gene; (ii) identification of rare mutations in several genes such as Prostaglandin I2 Receptor (PTGIR) and Collagen type V alpha 1 chain (COL5A1) genes; (iii) documentation of mild Connective-Tissue Disease-like features and increased levels of Transforming Growth Factor-beta in patients with FMD; (iv) identification of a tentative proteo-genomic signature of the disease. All elements are thus in place to further dissect the pathophysiology of FMD and related diseases, refine clinical characterization, identify predictors of complications and improve screening, management and follow-up.
Unravelling the clinical characteristics, genetic and molecular basis of FMD nevertheless requires large numbers of well characterized patients. In order to address these challenges and generate new evidence pertaining to FMD and associated diseases, we aimed to create an overarching resource and study named "the European/International FMD Registry and Initiative" (acronym: FEIRI).
The objectives of FEIRI are:
To describe the demographic and arterial characteristics of FMD and related diseases at a global scale and according to countries and/or ethnic origin
To identify environmental/ hormonal factors and exposures associated with the onset and progression of FMD
To evaluate the incidence and predictors of novel FMD lesions and complications
To provide evidence-based algorithms for the diagnosis and optimal management and follow-up of patients with FMD
To explore the commonalities and differences between FMD, SCAD and so-called atypical FMD (patients with multiple dissections and/or aneurysms without string-of-beads, focal stenosis or evidence of inherited arteriopathy)
To contribute to the unravelling of genetic, proteomic and molecular mechanisms underlying FMD and related diseases
Participation to the FEIRI study implies:
Collection of demographic and standard-of-care clinical data, both retrospectively (from the diagnosis of FMD to signature of the informed consent) and prospectively (on the occasion of standard-of-care follow-up).
Optional participation (both for centres and patients) to a biobank implying collection of blood, urine and, in rare cases of intervention, tissue samples for genomic and proteomic analysis and identification of diagnostic and prognostic biomarkers of FMD.
Participants will be enrolled in centres from over 20 countries in Europe and beyond.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Alexandre Persu, MD-PhD
- Phone Number: 0032 2 764 63 06
- Email: alexandre.persu@uclouvain.be
Study Locations
-
-
-
Brussels, Belgium, 1200
- Recruiting
- Cliniques Universitaires Saint-Luc
-
Contact:
- Alexandre Persu, MD-PhD
- Phone Number: 0032 2 764 63 06
- Email: alexandre.persu@uclouvain.be
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
(i) Patients with established FMD, i.e at least one string-of-beads (multifocal FMD) or focal stenosis (focal FMD).
(ii) Patients with Spontaneous Coronary Artery Dissection (SCAD) in whom at least one lesion of multifocal FMD (string-of beads) in extra-coronary arteries has been identified ("SCAD-FMD").
(iii) Patients with so-called "atypical FMD" or "FMD-like presentation", i.e. patients presenting with at least one dissection or 2 aneurysms < 60-year-old, in the absence string-of-beads, focal stenosis or evidence of inherited arteriopathy.
Exclusion Criteria:
Diagnosis based only on ultrasound (need for computed tomographic angiography , magnetic resonance angiography or catheter-based angiography to confirm the diagnosis)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Cohort of patients with Fibromuscular Dysplasia
Intervention consists in blood/urine sampling
|
Blood sampling for genetic analysis aiming at unraveling the genetic basis of Fibromuscular Dysplasia
Blood/urine and in rare cases tissue sampling aiming at identifying biomarkers of Fibromuscular Dysplasia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wide-scale analysis of characteristics and progression of Fibromuscular Dysplasia
Time Frame: 10 years
|
Wide-scale analysis of baseline clinical characteristics and predictors of evolution/complications of Fibromuscular Dysplasia
|
10 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Alexandre Persu, MD-PhD, Cliniques Universitaires Saint-Luc
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015/28AOU/464
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromuscular Dysplasia
-
Assistance Publique Hopitaux De MarseilleCompletedRenal Artery Fibromuscular DysplasiaFrance
-
Shanghai Jiao Tong University School of MedicineRecruiting
-
Mayo ClinicWithdrawnSpontaneous Coronary Artery Dissection | Fibromuscular Dysplasia of Arteries | Segmental Arterial Mediolysis | Atherosclerosis of ArteryUnited States
-
Assistance Publique - Hôpitaux de ParisFondation pour la Recherche MédicaleCompleted
-
Icahn School of Medicine at Mount SinaiCompletedFibromuscular Dysplasia | Early Onset CADUnited States
-
University Hospital, ToulouseNot yet recruiting
-
Assistance Publique - Hôpitaux de ParisFondation de Recherche sur l'Hypertension ArtérielleCompletedFibromuscular DysplasiaFrance, Belgium
-
Assistance Publique - Hôpitaux de ParisFondation de Recherche sur l'Hypertension ArtérielleCompletedFibromuscular DysplasiaFrance, Belgium
-
Centre Hospitalier Universitaire de Saint EtienneCompletedRenal Artery Stenosis | Fibromuscular DysplasiaFrance
-
Icahn School of Medicine at Mount SinaiRecruitingSpontaneous Coronary Artery Dissection | Fibromuscular Dysplasia | Cervical Artery DissectionUnited States
Clinical Trials on Genetic dissection of Fibromuscular Dysplasia
-
Istituto Ortopedico RizzoliCompleted
-
Gaziosmanpasa Research and Education HospitalCompleted2D Ultrasound | Cavum Septum Pellucidum | Septooptic Dysplasia | Optic Chiasma | Willis PolygonTurkey
-
University Hospital Birmingham NHS Foundation TrustRecruitingPancreatic AdenocarcinomaUnited Kingdom
-
Duke UniversityGenentech, Inc.TerminatedPrimary Open Angle Glaucoma | Glaucoma | Glaucoma, SuspectUnited States
-
Istituto Clinico HumanitasRecruiting
-
Northwestern UniversityGeorgetown UniversityRecruitingChronic Kidney Diseases | Kidney Transplantation | Apolipoprotein L1United States
-
Tianjin Medical University Cancer Institute and...CompletedCarcinoma, Pancreatic DuctalChina
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMalignant Solid Neoplasm | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditionsUnited States
-
Imam Mohammad ibn Saud Islamic UniversityEnrolling by invitation